ETHICS ADVISORY BOARD

Illumina is committed to building our company with integrity and ethical business behavior.

What is Illumina’s Ethics Advisory Board?

Since 2008, Illumina convened an Ethics Advisory Board (EAB) to ensure Illumina acts ethically and justly in its business operations. The EAB meets as necessary, but at least yearly, to advise and provide recommendations regarding ethical issues involving Illumina’s existing, emerging, and prospective products, services, and processes both from a research and clinical perspective. This includes providing strategic advice to Illumina regarding emerging ethical issues, policies, and regulations relevant to the genomic industry.

Morris Foster, Ph.D.
Chairman

Morris is a medical anthropologist who is Vice President for Research at Old Dominion University. His research in medical anthropology has focused on the involvement of communities and groups in genetic studies, on the relationship between race and genetics and on the utility of personal genomic information.

Jeffrey Botkin, M.D., M.P.H.

Jeff is a Professor of Pediatrics at the University of Utah and an Adjunct Professor of Human Genetics. He is also the Associate Vice President for Research Integrity at the University of Utah and was formerly the Chief of the Division of Medical Ethics and Humanities in the Department of Internal Medicine. His research and publications are focused on research ethics, genetic testing for cancer susceptibility, newborn screening, and prenatal diagnosis.

Dov Fox, J.D.

Dov is Professor of Law at the University of San Diego, where he directs the Center for Health Law Policy & Bioethics. His research considers matters of genome privacy, DNA forensics, cognitive neuroscience, and FDA regulation. His latest book is Birth Rights and Wrongs: How Medicine and Technology and Remaking Reproduction and the Law (Oxford University Press).

Leslie Biesecker, M.D.

Les is a clinical and molecular geneticist and is the chief of the Medical Genomics and Metabolic Genetics Branch at the National Human Genome Research Institute (NHGRI) of the National Institutes of Health. Dr. Biesecker directs the NIH ClinSeq project with goals to improve medical care for patients and provide generalized knowledge about genetic disease.

Nita Farahany, J.D., Ph.D.

Nita is a Professor of Law & Philosophy at Duke University, and the Director of Duke Science & Society program. She is a leading scholar on the ethical, legal, and social implications of biosciences and emerging technologies, particularly those related to neuroscience and behavioral genetics.

Alastair Kent OBE

Alastair was the executive director of Genetic Alliance UK (the UK alliance of over 200 patient support groups for patients and families with rare and genetic disorders) for almost 25 years.

Since retiring from Genetic Alliance UK Alastair has continued to work on behalf of patients and families affected by rare and genetic diseases. He is currently co-chair of the UK Rare Disease Policy Board at the Department of Health and Social Care and Chair of the Rare Diseases Advisory Group for NHS England.